<it>HFE </it>C282Y and H63D in adults with malignancies in a community medical oncology practice

<p>Abstract</p> <p>Background</p> <p>We sought to compare frequencies of <it>HFE </it>C282Y and H63D alleles and associated odds ratios (OR) in 100 consecutive unrelated white adults with malignancy to those in 318 controls.</p> <p>Methods</p&...

Full description

Bibliographic Details
Main Authors: Barton James C, Bertoli Luigi F, Acton Ronald T
Format: Article
Language:English
Published: BMC 2004-02-01
Series:BMC Cancer
Subjects:
Online Access:http://www.biomedcentral.com/1471-2407/4/6
id doaj-f5a7ec3521b24c7cad065ae580614241
record_format Article
spelling doaj-f5a7ec3521b24c7cad065ae5806142412020-11-24T20:53:39ZengBMCBMC Cancer1471-24072004-02-0141610.1186/1471-2407-4-6<it>HFE </it>C282Y and H63D in adults with malignancies in a community medical oncology practiceBarton James CBertoli Luigi FActon Ronald T<p>Abstract</p> <p>Background</p> <p>We sought to compare frequencies of <it>HFE </it>C282Y and H63D alleles and associated odds ratios (OR) in 100 consecutive unrelated white adults with malignancy to those in 318 controls.</p> <p>Methods</p> <p>Data from patients with more than one malignancy were analyzed according to each primary malignancy. For the present study, OR ≥2.0 or ≤0.5 was defined to be increased or decreased, respectively.</p> <p>Results</p> <p>There were 110 primary malignancies (52 hematologic neoplasms, 58 carcinomas) in the 100 adult patients. Allele frequencies were similar in patients and controls (C282Y: 0.0850 vs. 0.0896, respectively (OR = 0.9); H63D: 0.1400 vs. 0.1447, respectively (OR = 0.9)). Two patients had hemochromatosis and C282Y homozygosity. With C282Y, increased OR occurred in non-Hodgkin lymphoma, myeloproliferative disorders, and adenocarcinoma of prostate (2.0, 2.8, and 3.4, respectively); OR was decreased in myelodysplasia (0.4). With H63D, increased OR occurred in myeloproliferative disorders and adenocarcinomas of breast and prostate (2.4, 2.0, and 2.0, respectively); OR was decreased in non-Hodgkin lymphoma and B-chronic lymphocytic leukemia (0.5 and 0.4, respectively).</p> <p>Conclusions</p> <p>In 100 consecutive adults with malignancy evaluated in a community medical oncology practice, frequencies of <it>HFE </it>C282Y or H63D were similar to those in the general population. This suggests that C282Y or H63D is not associated with an overall increase in cancer risk. However, odds ratios computed in the present study suggest that increased (or decreased) risk for developing specific types of malignancy may be associated with the inheritance of <it>HFE </it>C282Y or H63D. Study of more patients with these specific types of malignancies is needed to determine if trends described herein would remain and yield significant differences.</p> http://www.biomedcentral.com/1471-2407/4/6breast cancerC282Ycancerironhemochromatosis<it>HFE</it>H63Dmalignancymyelomamyeloproliferative disordernon-Hodgkin lymphoma
collection DOAJ
language English
format Article
sources DOAJ
author Barton James C
Bertoli Luigi F
Acton Ronald T
spellingShingle Barton James C
Bertoli Luigi F
Acton Ronald T
<it>HFE </it>C282Y and H63D in adults with malignancies in a community medical oncology practice
BMC Cancer
breast cancer
C282Y
cancer
iron
hemochromatosis
<it>HFE</it>
H63D
malignancy
myeloma
myeloproliferative disorder
non-Hodgkin lymphoma
author_facet Barton James C
Bertoli Luigi F
Acton Ronald T
author_sort Barton James C
title <it>HFE </it>C282Y and H63D in adults with malignancies in a community medical oncology practice
title_short <it>HFE </it>C282Y and H63D in adults with malignancies in a community medical oncology practice
title_full <it>HFE </it>C282Y and H63D in adults with malignancies in a community medical oncology practice
title_fullStr <it>HFE </it>C282Y and H63D in adults with malignancies in a community medical oncology practice
title_full_unstemmed <it>HFE </it>C282Y and H63D in adults with malignancies in a community medical oncology practice
title_sort <it>hfe </it>c282y and h63d in adults with malignancies in a community medical oncology practice
publisher BMC
series BMC Cancer
issn 1471-2407
publishDate 2004-02-01
description <p>Abstract</p> <p>Background</p> <p>We sought to compare frequencies of <it>HFE </it>C282Y and H63D alleles and associated odds ratios (OR) in 100 consecutive unrelated white adults with malignancy to those in 318 controls.</p> <p>Methods</p> <p>Data from patients with more than one malignancy were analyzed according to each primary malignancy. For the present study, OR ≥2.0 or ≤0.5 was defined to be increased or decreased, respectively.</p> <p>Results</p> <p>There were 110 primary malignancies (52 hematologic neoplasms, 58 carcinomas) in the 100 adult patients. Allele frequencies were similar in patients and controls (C282Y: 0.0850 vs. 0.0896, respectively (OR = 0.9); H63D: 0.1400 vs. 0.1447, respectively (OR = 0.9)). Two patients had hemochromatosis and C282Y homozygosity. With C282Y, increased OR occurred in non-Hodgkin lymphoma, myeloproliferative disorders, and adenocarcinoma of prostate (2.0, 2.8, and 3.4, respectively); OR was decreased in myelodysplasia (0.4). With H63D, increased OR occurred in myeloproliferative disorders and adenocarcinomas of breast and prostate (2.4, 2.0, and 2.0, respectively); OR was decreased in non-Hodgkin lymphoma and B-chronic lymphocytic leukemia (0.5 and 0.4, respectively).</p> <p>Conclusions</p> <p>In 100 consecutive adults with malignancy evaluated in a community medical oncology practice, frequencies of <it>HFE </it>C282Y or H63D were similar to those in the general population. This suggests that C282Y or H63D is not associated with an overall increase in cancer risk. However, odds ratios computed in the present study suggest that increased (or decreased) risk for developing specific types of malignancy may be associated with the inheritance of <it>HFE </it>C282Y or H63D. Study of more patients with these specific types of malignancies is needed to determine if trends described herein would remain and yield significant differences.</p>
topic breast cancer
C282Y
cancer
iron
hemochromatosis
<it>HFE</it>
H63D
malignancy
myeloma
myeloproliferative disorder
non-Hodgkin lymphoma
url http://www.biomedcentral.com/1471-2407/4/6
work_keys_str_mv AT bartonjamesc ithfeitc282yandh63dinadultswithmalignanciesinacommunitymedicaloncologypractice
AT bertoliluigif ithfeitc282yandh63dinadultswithmalignanciesinacommunitymedicaloncologypractice
AT actonronaldt ithfeitc282yandh63dinadultswithmalignanciesinacommunitymedicaloncologypractice
_version_ 1716796670522425344